Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone®) for the prevention of malaria

BioDrugs

Volumn 17, Issue SUPPL. 1, 2003, Pages 23-28

  Kain, Kevin C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; CHOLERA VACCINE; CREATININE; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DOXYCYCLINE; DRUG METABOLITE; LIVER ENZYME; MEFLOQUINE; METOCLOPRAMIDE; NUCLEOSIDE ANALOG; PLACEBO; PRIMAQUINE; PROGUANIL; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TETRACYCLINE; TYPHOID VACCINE; UBIQUINOL CYTOCHROME C REDUCTASE; ZIDOVUDINE;

ABDOMINAL PAIN; BREAST FEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSECT BITE; MALARIA; MALARIA CONTROL; MENTAL DISEASE; MORTALITY; MOSQUITO; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COMPLIANCE; PHARMACOKINETICS; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; RELAPSE; RESPIRATORY CHAIN; REVIEW; TABLET; TRAVEL; TREATMENT FAILURE;

ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; MALARIA, FALCIPARUM; NAPHTHOQUINONES; RANDOMIZED CONTROLLED TRIALS; TRAVEL;

EID: 0037737838     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317001-00006     Document Type: Review

References (44)

1. World Health Organization (WHO). The world report 1999: making a difference. Geneva: WHO, 1999
2. Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med 2000; 342: 1716-25
3. Kain KC. Prophylactic drugs for malaria: why do we need another one? J Travel Med 1999; 6 Suppl. 1: S2-7
4. Greenberg AE, Lobel HO. Mortality from Plasmodium Falciparum malaria in travellers from the United States, 1959 to 1987. Ann Intern Med 1990; 113: 326-7
5. Newman RD, Barber AM, Roberts J, et al. Malaria surveillance: United States, 1999. MMWR Surveill Summ 2002; 51 (1): 15-28
6. Bradley DJ, Warhurst DC, Blaze M, et al. Malaria imported into the United Kingdom in 1996. Euro Surveill 1998; 3: 40-2
7. Kain KC, Macpherson DW, Kelton T, et al. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001; 164: 654-9
8. Mühlberger N, Jelinek T, Behrens RH, et al. Age is a risk factor for severe manifestations and fatal outcome in European patients with falciparum malaria: observations from TropNetEurop- and SIMPID-surveillance data [abstract MOP5002]. Program and abstracts of the 3rd European Conference on Tropical Medicine and International Health. Acta Tropica 2002; 83: 531
9. Centers for Disease Control and Prevention (CDC). Health information for international travel: 2001-2002. Atlanta: US Department of Health and Human Services, 2001
10. Canadian recommendations for the prevention and treatment of malaria among international travellers. Committee to Advise on Tropical Medicine and Travel (CATMAT), Laboratory for Disease Control. Can Commun Dis Rep 2000; 26 Suppl. 2: i-vi, 1-42
11. World Health Organization (WHO). International travel and health 2002. Geneva: WHO, 2002
12. Hay SI, Cox J, Rogers DJ, et al. Climate change and the resurgence of malaria in the East African highlands. Nature 2002; 415: 905-9
13. Ohrt C, Ritchie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann Intern Med 1997; 126: 963-72
14. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341: 1299-303
15. Hill DR, Behrens RH, Bradley DJ. The risk of malaria in travellers to Thailand. Trans R Soc Trop Med Hyg 1996; 90: 680-1
16. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347 (1): 13-8
17. Soto J, Medina F, Dember N, et al. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis 1995; 21: 599-602
18. Ryan ET, Wilson M, Kain KC. Illness after international travel. N Engl J Med 2002; 347: 505-16
19. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94 Suppl. 1: S1-S90
20. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance I: currently recommended drug regimens. Clin Infect Dis 2001; 33: 226-34
21. Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance II: drugs that may be available in the future. Clin Infect Dis 2001; 33: 381-5
22. Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atorvaquone (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95: 429-32
23. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43: 1334-9
24. Beerahee M, Clarke P, Overbosch D, et al. Prophylaxis with Malarone (atovaquone and proguanil hydrochloride) in non-immune subjects 65 years age and older. Proceedings of the Third European Congress on Tropical Medicine and International Health; 2002 Sep 8-11; Lisbon, Portugal
25. Product Information. Malarone brand of atovaquone and proguanil hydrochloride tablets. Research Triangle Park: GlaxoSmithKline, 2002
26. Shapiro TA, Ranasinha CD, Kumar N, et al. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60: 831-6
27. Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27: 494-9
28. Lell B, Luckner D, Ndjave M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351: 709-13
29. Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60: 521-5
30. Hogh B, Clarke P, Camus D, et al. Atovaquone/proguanil versus chloroquine/proguanil for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Lancet 2000; 356: 1888-94
31. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus. mefloquine for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Clin Infect Dis 2001; 33: 1015-21
32. Ling J, Baird JK, Fryauff DJ, et al. Randomized, double-blind, placebo-controlled evaluation of Malarone for prophylaxis of P. vivax and P. falciparum malaria in non-immune transmigrants to Papua. Clin Infect Dis 2002; 35: 825-33
33. van der Berg JD, Duvenage CS, Roskell NS, et al. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum in South Africa. Clin Ther 1999; 21: 741-9
34. Faucher JF, Binder R, Missinou MA, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147-54
35. Nasveld PE, Edstein MD, Kitchener SJ, et al. Comparison of the effectiveness of atovaquone/proguanil combination and doxycycline in the chemoprophylaxis of malaria in Australian Defence Force personnel [abstract 16]. Program and abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2002 Oct 29-Nov 2; Houston, Texas: 139
36. Camus D, Malvy D, Schilthuis H, et al. Atovaquone/proguanil versus chloroquine/proguanil or mefloquine in clinical trials of non-immune paediatric travellers 11-40kg. Proceedings of the Third European Congress on Tropical Medicine and International Health; 2002 Sep 8-11; Lisbon, Portugal
37. van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002; 35: 1498-504
38. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 62-6
39. Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44: 2100-8
40. Fivelman QL, Butcher GA, Adagu IS, et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002; 1: 1
41. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of Atovaquone-proguanil (Malarone™) resistant Plasmodium falciparum malaria acquired by a non-immune traveler to East Africa. Clin Infect Dis 2003. In press
42. Schlagenhauf P, Tschopp A, Johnson R, et al. Randomised, double-blind, four-arm study of the adverse event profiles of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa [abstract 568]. Am J Trop Med Hyg 2002; 67: 354-5
43. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-6
44. Lee BL, Tauber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996; 59: 14-21